Inhibikase Therapeutics Inc (IKT) Stock: A Closer Look at the Market Potential

6h ago, source: newsheater

For stock market investors that means buying up cheap small cap stocks like these with huge upside potential. We've set up an alert service to help smart investors take full advantage of the small cap ...

Q4 2023 Inhibikase Therapeutics Inc Earnings Call

25d ago, source: Yahoo Finance

Milton Werner; President & CEO; Inhibikase Therapeutics, Inc. Garth Lees-Rolfe; CFO; Inhibikase Therapeutics, Inc. Operator Ladies and gentlemen, thank you for standing by Greetings and welcome to ...

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

27d ago, source: Business Insider

BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase ...

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

20d ago, source: Business Insider

BOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage ...

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

5d ago, source: Morningstar

BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase ...

Inhibikase Therapeutics Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript

21d ago, source: Yahoo Finance

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript March 28, 2024 Inhibikase Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the ...

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

4d ago, source: Stockhouse

BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

27d ago, source: Stockhouse

BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

25d ago, source: Seeking Alpha

Ladies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics Fourth Quarter and Full Year 2023 Financial Results. At this time, all participants will be in ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript

21d ago, source: Insider Monkey

Inhibikase Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for ...